Abstract: The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.

Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.

Abstract: The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.

Abstract: The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.

Abstract: The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.

Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases.

Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.

Abstract: The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.

Abstract: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor ?-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLII68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.

Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases.

Abstract: The present invention concerns materials and methods for characterizing monoclonal immunoglobulin specificity of a Monoclonal Gammopathy of Undetermined Significance (MGUS) or Myeloma patients using a protein microarray comprising (a) a substrate, (b) antigens immobilized on the substrate, said antigens being selected from a defined group consisting of infectious agent antigens and/or self-antigens. In particular said protein microarray may be used to improve diagnosis, for the prognosis of myeloma or MGUS, for preventing transformation of MGUS toward myeloma, for adapting treatment of MGUS and myeloma or for monitoring the response to therapy of MGUS and myeloma patients.

Abstract: The present invention relates to a method for predicting the responsiveness of a patient to an anti-TNF? antibody treatment.

Abstract: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor ?-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLII68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.

Abstract: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor ?-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLIL68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.

Abstract: The present invention relates to the stimulation of the IL-15R beta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.

Abstract: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor ?-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLIL68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.

Abstract: The present invention relates to new IL-11 muteins of which site I hydrophobocity has been increased. These muteins act as IL-11 agonist or hyperagonist, and are notably useful as anti-thrombocytopenia agents, and as agents improving the resistance of an organism to the deleterious in vivo effects induced by radiation or chemotherapy during the treatment of cancer or for the preparation of patient to transplantation.